Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-109 in Advanced Colorectal Cancer
NCT00824161Phase 2Terminated
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2009
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radgocitabine in colorectal cancer (CRC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Progression Free Survival at 3 months. Started Jan 2009; status: terminated.
02
Drugs
radgocitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00824161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00824161.